Ignyte Acquisition Corp. Completes Business Combination with Peak Bio Co., Ltd.

Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Begins Nasdaq Trading as BIOT

July 23, 2026

Healthcare Services

Instinct Bio Technical Company Holdings Inc. completed its previously announced business combination with Relativity Acquisition Corp., positioning the company as a publicly listed regenerative medicine and longevity platform. Following closing, Instinct Bio’s common stock and warrants began trading on Nasdaq on July 24, 2026 under tickers BIOT and BIOTW.

AbbVie Acquires Apogee Therapeutics for $10.9 Billion

June 22, 2026

Biotechnology

AbbVie entered into a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion ($135.11 per share). The deal is intended to deepen AbbVie’s immunology portfolio and expand its clinical presence in respiratory diseases, with Apogee’s lead program zurilokibart (APG777) targeting IL-13 for atopic dermatitis and its pipeline including APG273 for asthma. Closing was expected in Q3 2026, subject to customary regulatory and shareholder approvals; AbbVie later announced completion on Sept. 3, 2026.

Copley Acquisition Corp and Aditxt Agree to Take Ignite Proteomics Public via Business Combination Valuing Company at ~$150 Million

June 9, 2026

Biotechnology

Copley Acquisition Corp and Ignite Proteomics (a wholly owned subsidiary of Aditxt) have entered into a definitive business combination agreement to take Ignite public. The transaction values Ignite at an implied equity value of approximately $150 million and is expected to create a newly formed holding company (Ignite Proteomics Holdings) with listings on the NYSE, with Ignite expected to become an independent public company following closing.

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Invaio Sciences Acquires Peptyde Bio

December 7, 2023

Biotechnology

Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.

Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

December 20, 2021

Healthcare Services

International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.